Oral Tasocitinib Demonstrates Statistically Significant Response by 12 Weeks in Phase 2 Study of People With Moderate to Severe Plaque PsoriasisBy Pfizer Inc., PRNE
Wednesday, October 6, 2010
Results Presented at the Annual Meeting of the European Academy of Dermatology and Venereology in Gothenburg, Sweden
NEW YORK, October 7, 2010 - Pfizer Inc. (NYSE: PFE) today announced that data from a Phase 2 efficacy
and safety study of tasocitinib (proposed INN name for CP-690,550), the
company's investigational oral JAK inhibitor, met its primary endpoint of a
statistically significant greater proportion of patients achieving at least a
75 percent reduction from baseline in PASI (Psoriasis Area and Severity
Index) at week 12 in individuals with chronic moderate to severe plaque
psoriasis. At week 12, PASI 75 responses for tasocitinib 2, 5 and 15 mg twice
daily groups were 25.0%, 40.8% and 66.7% respectively, versus placebo, 2.0%
(all doses, p<0.001). As early as week 4, treatment with 5 and 15 mg twice
daily of tasocitinib significantly improved patient reported health-related
quality of life outcomes. These results were presented in two posters at the
annual meeting of the European Academy of Dermatology and Venereology (EADV).
(Logo: photos.prnewswire.com/prnh/20100416/PFIZERLOGO ) (Logo: www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO )
The double-blind, placebo-controlled, dose-ranging Phase 2 study was
conducted in 197 adult patients with moderate to severe plaque psoriasis.
Study participants were randomized to receive 2, 5 or 15 mg tasocitinib or
placebo twice daily. In the study, the most frequently reported
treatment-emergent adverse events were upper respiratory tract infection and
Three patients experienced a total of five serious adverse events during
the study. Dose dependent decreases in mean neutrophil counts and hemoglobin
values and increases in mean LDL, HDL and total cholesterol levels were
About Plaque Psoriasis
Psoriasis is a chronic autoimmune skin disease that affects 125 million
people worldwide.(1) Plaque psoriasis is the most common form of the disease,
accounting for about 80 percent of cases.(2) It is characterized by raised,
inflamed, red lesions covered by a silvery white scale that can be very itchy
and painful.(2) Psoriasis is typically found on the elbows, knees, scalp and
lower back.(2) For people who have moderate to severe psoriasis, quality of
life can suffer significantly due to pain, itching and emotional impacts from
the disease.(3) Patients also report dissatisfaction with traditional
psoriasis therapies. According to published studies, 10-50% of people with
psoriasis who used traditional therapies reported an inadequate response to
treatment, and 42% said they were dissatisfied with their treatment
Efficacy was assessed at 12 weeks using the PASI scale (PASI 75
represents a 75 percent improvement from baseline in the psoriasis area and
severity index), and Physician Global Assessment (PGA) which evaluated the
percentage of patients scoring "clear" or "almost clear" in their psoriasis
symptoms. The results are as follows:
PGA "clear" or "almost clear" PASI 50 (% of PASI 75 (% of PASI 90 (% of (% of Dose patients) patients) patients) patients) 2 mg 39.6* 25.0*** 14.6** 24.5* 5 mg 65.3* 40.8*** 18.4** 40.8* 15 mg 87.5* 66.7*** 33.3** 72.9* ----- ----- ------- ------ ----- Placebo 20.0 2.0 0.0 10.0 ------- ---- --- --- ----
*p less than or equal to 0.05 **p<0.01 *** p<0.001
Patient health-related quality of life was measured using the Dermatology
Life Quality Index (DLQI); and the Physical (PCS) and Mental Component Scores
(MCS) of the Short Form-36 questionnaire (SF-36 version 2, acute), a measure
of individuals' physical and mental health and well-being.(5) Patient
self-assessment of disease activity was measured using a 5-category Patient
Global Assessment (PtGA) of psoriasis. These results at week 12 are as
DLQI PCS MCS PtGA (mean (mean (mean "clear" change in change in change in or "almost score from score from score from clear" score Dose baseline) baseline) baseline) (%) 2 mg -7.74** 1.06 2.29* 35.1** 5 mg -7.26** 3.44* 2.54* 38.5** 15 mg -9.40** 3.31* 3.63* 74.4** ----- ------- ----- ----- ------ Placebo -2.01 -1.17 -2.86 2.9 ------- ----- ----- ----- ---
*p<0.05 ** p less than or equal to 0.0001
"Plaque psoriasis affects millions of people globally and can have a
negative impact on a person's quality of life,"(6) said Saeed Fatenejad,
M.D., VP, Clinical Development & Medical Affairs (CDMA), Disease Area Lead
for Inflammation, Pfizer Specialty Care Business Unit. "We are encouraged by
the results seen in the Phase 2 study and look forward to further studying
tasocitinib in the recently initiated Phase 3 program called the OPT trials."
Tasocitinib is a Janus Kinase (JAK) inhibitor. It is believed that the
JAK pathways play an important role in the psoriasis disease cascade.
Researchers are conducting clinical trials to test the hypothesis that
inhibiting the JAK pathways modulates the immune and inflammatory responses
involved in psoriasis, which may lead to clinically meaningful improvement
More than 4,000 people have participated in tasocitinib clinical trials
to date. The most frequently reported adverse events include headaches,
infections and gastrointestinal symptoms such as nausea, vomiting and
diarrhea: most were mild to moderate in severity and were manageable with
routine medical care.
Pfizer has initiated its study of tasocitinib in people with chronic
moderate to severe plaque psoriasis in a Phase 3 program called the OPT (Oral
Psoriasis Treatment) Trials to further characterize the efficacy and safety
Tasocitinib is also being studied for the potential treatment of
rheumatoid arthritis in a group of trials called the ORAL trials
(www.ORALtrials.com). Additionally, tasocitinib is being studied in dry eye,
Crohn's disease, ulcerative colitis and solid organ transplant.
Tasocitinib was discovered by Pfizer scientists in the company's Groton,
Connecticut laboratories and is being developed solely by Pfizer.
Pfizer Inc.: Working together for a healthier world(TM)
At Pfizer, we apply science and our global resources to improve health
and well-being at every stage of life. We strive to set the standard for
quality, safety and value in the discovery, development and manufacturing of
medicines for people and animals. Our diversified global health care
portfolio includes human and animal biologic and small molecule medicines and
vaccines, as well as nutritional products and many of the world's best-known
consumer products. Every day, Pfizer colleagues work across developed and
emerging markets to advance wellness, prevention, treatments and cures that
challenge the most feared diseases of our time. Consistent with our
responsibility as the world's leading biopharmaceutical company, we also
collaborate with health care providers, governments and local communities to
support and expand access to reliable, affordable health care around the
world. For more than 150 years, Pfizer has worked to make a difference for
all who rely on us. To learn more about our commitments, please visit us at
DISCLOSURE NOTICE: The information contained in this release is as of
October 7, 2010. Pfizer assumes no obligation to update any forward-looking
statements contained in this release as the result of new information or
future events or developments.
This release contains forward-looking information about a product in
development, tasocitinib, including its potential benefits as a treatment for
psoriasis, certain other diseases and solid organ transplant, that involves
substantial risks and uncertainties. Such risks and uncertainties include,
among other things, the uncertainties inherent in research and development;
decisions by regulatory authorities regarding whether and when to approve any
drug applications that may be filed for tasocitinib as well as their
decisions regarding labeling and other matters that could affect its
availability or commercial potential; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer's
Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in
its reports on Form 10-Q and Form 8-K.
(1) National Psoriasis Foundation. Statistics.
www.psoriasis.org/netcommunity/learn_statistics. Accessed on July 1,
(2) National Psoriasis Foundation. Types of Psoriasis.
www.psoriasis.org/netcommunity/learn_types. Accessed June 24, 2010.
(3) Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much
disability as other major diseases. Journal of American Academy of
Dermatology. 1999 Sep; 41:401-407.
(4) Christophers et al. The unmet treatment need for moderate to severe
psoriasis: results of a survey and chart review. Journal of European
Dermatology and Venereology. 2006 Sep;20(8):921-5.
(5) Quality Metric Incorporated.SF-36 Health Survey Update.
www.sf-36.org/tools/sf36.shtml. Accessed on July 19, 2010.
(6) Kimball et al. National Foundation clinical consensus on psoriasis
comorbidities and recommendations for screening. Journal of American Academy
of Dermatology. 2008 Jun;58(6):1031-42.
Media: Gwen Fisher, O: +1-484-865-5160, M: +1-215-407-1548, Gwen.Fisher at pfizer.com; or Investor Contact: Suzanne Harnett, O:+1-212-733-8009, M: +1-646-256-9250, Suzanne.Harnett at pfizer.com
Tags: New York, October 7, Pfizer Inc., Western Europe